The invention provides a method for culturing mammalian cells. The method provides greater control over cell o growth to achieve high product titer cell cultures.

The present invention provides universal donor cellular populations derived from umbilical cords possessing ability to elicit immune modulation and evoke regeneration when administered into a mammalian host. Generation of cellular products for clinical use are provided including methodologies of expansion, characterization, and means of therapeutic implementation.

Methods for generating in culture of cells resembling mammalian trophectoderm-lineage cells from mammalian pluripotent stem cells are provided, along with the related compositions.

Provided is a temporary treatment medium for inhibiting embryo developmental arrest due to manipulation of an embryo or the like. A temporary treatment medium according to the present invention reduces damage to an in-vitro culture due to manipulation thereof, said in-vitro culture containing one of pluripotent stem cells, reproductive cells, a fertilized egg, and an embryo or any combination thereof. For this purpose, the temporary treatment medium contains a cytoskeleton regulator and/or an apoptosis inhibitor. The cytoskeleton regulator and/or the apoptosis inhibitor is preferably an Rho kinase inhibitor. Specifically, a Rock inhibitor can be used as the Rho kinase inhibitor. The Rock inhibitor is, for example, Y-27632. The temporary treatment medium is used for treating an in-vitro culture for a specific period before and/or after manipulation involving damage thereto.

Embodiments of the disclosure encompass systems, methods, and compositions for producing exosomes from primed mesenchymal stem cells that are expanded in the presence of IFNγ, TNFα, IL-1β, and IL-17. The systems, methods, and compositions ay occur in an automated cell expansion system that allows for controllable parameters and from which cells and exosomes may be harvested at one or more times as part of a particular regimen. In specific embodiments, the exosomes may be provided to an individual in need thereof, including in some cases when the exosomes comprise one or more therapeutic agents.

Provided are methods of deriving a mammalian livestock pluripotent stem cells line, by (a) ex-vivo culturing a mammalian livestock embryo of at least 7 days post-fertilization for a culturing period of at least 4 days and no more than until 21 days post-fertilization so at to obtain an embryo comprising epiblast cell and/or late stage pluripotent stem cell; (b) isolating from the embryo the epiblast cell and/or the late stage pluripotent stem cell, and (c) culturing the epiblast cell and/or the late-stage pluripotent stem cell under conditions suitable for expansion of undifferentiated mammalian livestock pluripotent stem cells to thereby obtain a population of mammalian livestock pluripotent stem cells. Also provided are isolated mammalian livestock pluripotent stem cells, and cells differentiated therefrom.

Disclosed herein is a formulation comprising an extracellular vesicle (EV), and a therapeutic active agent induced or embedded in the EV. According to preferred embodiments of the present disclosure, the EV is isolated from umbilical cord mesenchymal stem cells, and the active agent may be a growth factor, an immune-modulating agent, a small molecule, an siRNA, cDNA or a plant ingredient; for example, curcumin. Also disclosed herein are methods for producing the present formulation, and uses of the present formulation in the treatment of various diseases.

The method for automated cell positioning can include: sampling a video of a scene having a gamete, tracking the gamete, and positioning the gamete within a target region. The method can optionally include: determining attribute values for the gamete, selecting the gamete, reorienting the gamete, and/or manipulating the gamete, and/or any suitable steps.

The present invention provides methods and compostions to improve the efficiency of somatic cell nuclear transfer (SCNT). There is increasing evidence that the epigenetic state of donor nuclei has a significant impact on potential of nuclear transfer embryos to develop into blastocysts, from which pluripotent stem cells are derived. Strategic application of histone agents, capable of altering epigenetic state such as methylation, allows zygotic activation and robust blastocyst generation.

The invention relates to a device for isolating stem cells from fetal tissues, which device has an incubation chamber, at least one pump, at least one reservoir for a tissue break-down solution, at least one reservoir for a rinsing solution, optionally a control unit, optionally a means for removing contaminants, and optionally a means for expansion of the isolated stem cells. The invention further relates to a method for isolating stem cells from fetal tissue, which method comprises, among other things, the mechanical dissociation and the enzymatic digestion of the fetal tissue and optionally density gradient centrifugation for removing contaminants. The device and the method according to the invention are particularly suitable for isolating mesenchymal stem cells from fetal tissues, such as umbilical cord tissue, placenta tissue, or fetal lung tissue.